Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver

H. Richard Alexander, David L. Bartlett, Steven K. Libutti, Douglas L. Fraker, Tammy Moser, Steven A. Rosenberg

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Purpose: To evaluate efficacy and systemic and regional toxicities of hyperthermic isolated hepatic perfusion (IHP) using tumor necrosis factor (TNF) and melphalan for the treatment of unable primary or metastatic cancers confined to the liver. Patients and Methods: Thirty-four patients (18 men and 16 women; mean age, 49 years) underwent a 60-minute hyperthermic (39.5°to 40.0°C) IHP performed by laparotomy that used TNF 1.0 mg and melphalan 1.5 mg/kg. Perfusion inflow was through the gastroduodenal artery and outflow was from a cannula positioned in an isolated segment of retrohepatic inferior vena cava (IVC). Infrahepatic IVC and portal venous blood flow were shunted to the axillary vein using an external venoveno bypass circuit. Complete vascular isolation of the liver was confirmed by an 1-131-labelled human serum albumin monitoring technique. Results: There was no operative mortality. Seventy-five percent of patients had reversible grade III or IV (National Cancer Institute Common Toxicity Criteria) hepatic toxicity with one treatment-related mortality (3%) because of hepatic venoocclusive disease. In 33 assessable patients, the overall response rote was 75% (complete response, one patient [3%]; partial response, 26 patients [72%]). With a median potential follow-up of 15 months, the mean duration of response was 9 months (range, 2 to 30 months). Conclusion: IHP with TNF and melphalan results in significant regression of bulky hepatic cancers confined to the liver in the majority of patients. Based on these initial results, further refinement of this treatment technique is warranted; perhaps by the combination of IHP with other regional treatment strategies to provide long- term control of unresectable cancers confined to liver.

Original languageEnglish (US)
Pages (from-to)1479-1489
Number of pages11
JournalJournal of Clinical Oncology
Volume16
Issue number4
StatePublished - Apr 1998
Externally publishedYes

Fingerprint

Melphalan
Tumor Necrosis Factor-alpha
Perfusion
Liver
Neoplasms
Inferior Vena Cava
Axillary Vein
National Cancer Institute (U.S.)
Mortality
Therapeutics
Liver Neoplasms
Serum Albumin
Laparotomy
Blood Vessels
Arteries

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Alexander, H. R., Bartlett, D. L., Libutti, S. K., Fraker, D. L., Moser, T., & Rosenberg, S. A. (1998). Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. Journal of Clinical Oncology, 16(4), 1479-1489.

Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. / Alexander, H. Richard; Bartlett, David L.; Libutti, Steven K.; Fraker, Douglas L.; Moser, Tammy; Rosenberg, Steven A.

In: Journal of Clinical Oncology, Vol. 16, No. 4, 04.1998, p. 1479-1489.

Research output: Contribution to journalArticle

Alexander, HR, Bartlett, DL, Libutti, SK, Fraker, DL, Moser, T & Rosenberg, SA 1998, 'Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver', Journal of Clinical Oncology, vol. 16, no. 4, pp. 1479-1489.
Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. Journal of Clinical Oncology. 1998 Apr;16(4):1479-1489.
Alexander, H. Richard ; Bartlett, David L. ; Libutti, Steven K. ; Fraker, Douglas L. ; Moser, Tammy ; Rosenberg, Steven A. / Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 4. pp. 1479-1489.
@article{ca5a418ce3e741519a75298f31acdd91,
title = "Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver",
abstract = "Purpose: To evaluate efficacy and systemic and regional toxicities of hyperthermic isolated hepatic perfusion (IHP) using tumor necrosis factor (TNF) and melphalan for the treatment of unable primary or metastatic cancers confined to the liver. Patients and Methods: Thirty-four patients (18 men and 16 women; mean age, 49 years) underwent a 60-minute hyperthermic (39.5°to 40.0°C) IHP performed by laparotomy that used TNF 1.0 mg and melphalan 1.5 mg/kg. Perfusion inflow was through the gastroduodenal artery and outflow was from a cannula positioned in an isolated segment of retrohepatic inferior vena cava (IVC). Infrahepatic IVC and portal venous blood flow were shunted to the axillary vein using an external venoveno bypass circuit. Complete vascular isolation of the liver was confirmed by an 1-131-labelled human serum albumin monitoring technique. Results: There was no operative mortality. Seventy-five percent of patients had reversible grade III or IV (National Cancer Institute Common Toxicity Criteria) hepatic toxicity with one treatment-related mortality (3{\%}) because of hepatic venoocclusive disease. In 33 assessable patients, the overall response rote was 75{\%} (complete response, one patient [3{\%}]; partial response, 26 patients [72{\%}]). With a median potential follow-up of 15 months, the mean duration of response was 9 months (range, 2 to 30 months). Conclusion: IHP with TNF and melphalan results in significant regression of bulky hepatic cancers confined to the liver in the majority of patients. Based on these initial results, further refinement of this treatment technique is warranted; perhaps by the combination of IHP with other regional treatment strategies to provide long- term control of unresectable cancers confined to liver.",
author = "Alexander, {H. Richard} and Bartlett, {David L.} and Libutti, {Steven K.} and Fraker, {Douglas L.} and Tammy Moser and Rosenberg, {Steven A.}",
year = "1998",
month = "4",
language = "English (US)",
volume = "16",
pages = "1479--1489",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver

AU - Alexander, H. Richard

AU - Bartlett, David L.

AU - Libutti, Steven K.

AU - Fraker, Douglas L.

AU - Moser, Tammy

AU - Rosenberg, Steven A.

PY - 1998/4

Y1 - 1998/4

N2 - Purpose: To evaluate efficacy and systemic and regional toxicities of hyperthermic isolated hepatic perfusion (IHP) using tumor necrosis factor (TNF) and melphalan for the treatment of unable primary or metastatic cancers confined to the liver. Patients and Methods: Thirty-four patients (18 men and 16 women; mean age, 49 years) underwent a 60-minute hyperthermic (39.5°to 40.0°C) IHP performed by laparotomy that used TNF 1.0 mg and melphalan 1.5 mg/kg. Perfusion inflow was through the gastroduodenal artery and outflow was from a cannula positioned in an isolated segment of retrohepatic inferior vena cava (IVC). Infrahepatic IVC and portal venous blood flow were shunted to the axillary vein using an external venoveno bypass circuit. Complete vascular isolation of the liver was confirmed by an 1-131-labelled human serum albumin monitoring technique. Results: There was no operative mortality. Seventy-five percent of patients had reversible grade III or IV (National Cancer Institute Common Toxicity Criteria) hepatic toxicity with one treatment-related mortality (3%) because of hepatic venoocclusive disease. In 33 assessable patients, the overall response rote was 75% (complete response, one patient [3%]; partial response, 26 patients [72%]). With a median potential follow-up of 15 months, the mean duration of response was 9 months (range, 2 to 30 months). Conclusion: IHP with TNF and melphalan results in significant regression of bulky hepatic cancers confined to the liver in the majority of patients. Based on these initial results, further refinement of this treatment technique is warranted; perhaps by the combination of IHP with other regional treatment strategies to provide long- term control of unresectable cancers confined to liver.

AB - Purpose: To evaluate efficacy and systemic and regional toxicities of hyperthermic isolated hepatic perfusion (IHP) using tumor necrosis factor (TNF) and melphalan for the treatment of unable primary or metastatic cancers confined to the liver. Patients and Methods: Thirty-four patients (18 men and 16 women; mean age, 49 years) underwent a 60-minute hyperthermic (39.5°to 40.0°C) IHP performed by laparotomy that used TNF 1.0 mg and melphalan 1.5 mg/kg. Perfusion inflow was through the gastroduodenal artery and outflow was from a cannula positioned in an isolated segment of retrohepatic inferior vena cava (IVC). Infrahepatic IVC and portal venous blood flow were shunted to the axillary vein using an external venoveno bypass circuit. Complete vascular isolation of the liver was confirmed by an 1-131-labelled human serum albumin monitoring technique. Results: There was no operative mortality. Seventy-five percent of patients had reversible grade III or IV (National Cancer Institute Common Toxicity Criteria) hepatic toxicity with one treatment-related mortality (3%) because of hepatic venoocclusive disease. In 33 assessable patients, the overall response rote was 75% (complete response, one patient [3%]; partial response, 26 patients [72%]). With a median potential follow-up of 15 months, the mean duration of response was 9 months (range, 2 to 30 months). Conclusion: IHP with TNF and melphalan results in significant regression of bulky hepatic cancers confined to the liver in the majority of patients. Based on these initial results, further refinement of this treatment technique is warranted; perhaps by the combination of IHP with other regional treatment strategies to provide long- term control of unresectable cancers confined to liver.

UR - http://www.scopus.com/inward/record.url?scp=0345596439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345596439&partnerID=8YFLogxK

M3 - Article

C2 - 9552055

AN - SCOPUS:0345596439

VL - 16

SP - 1479

EP - 1489

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -